Clarity Pharmaceuticals: From $1 to $9 a share - Could this eventually be a cure for prostate cancer? 

Listen to ASX-listed Clarity Pharmaceuticals Executive Chair Alan Taylor talk to Matt Birney on the Bulls N’ Bears Report about Clarity’s amazing clinical trial results that saw a complete response in one patient and lots with a 90 per cent plus reduction in signs of prostate cancer using “copper” based radiopharmaceuticals.